endogene.bio has successfully closed its seed funding round, securing significant investment to advance its work in biomarker discovery for female health. The round was led by Frontline Ventures, a well-known venture capital firm with a focus on early-stage AI, tech and life sciences companies, followed by the Atomico Angel fund and Zubi Capital, amongst others.

This funding will enable EndoGene.Bio to accelerate its research and development efforts, particularly in creating innovative solutions to address unmet needs in women’s healthcare. The successful seed round marks a pivotal step in the company’s growth and mission to transform female health diagnostics.

\